US EditionPublished • loading... • Updated
Feasibility trial shows promising results for renal assist device
Summary by Cardiovascular News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Feasibility trial shows promising results for renal assist device
Roivios has announced promising results from the first human trial of its JuxtaFlow renal assist device (RAD). The therapy has shown potential to improve outcomes for patients with acute decompensated heart failure and diuretic-resistant cardiorenal syndrome (CRS). The VOID-HF feasibility trial, published in the ASAIO Journal, enrolled seven patients across three US centres. JuxtaFlow is designed to apply controlled negative pressure directly to…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
